OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health reported Q1 2026 revenue of $124.2 million, down from $149.9 million in the prior year due to the sale of BioReference assets, while narrowing its operating loss to $51.0 million from $67.2 million. The company reaffirmed its full-year 2026 revenue guidance of $530 million to $560 million and highlighted clinical progress, including the initiation of Phase 1 trials for COVID-19 antibody MDX2301 and lymphoma treatment MDX2003.
Key figures
- Revenue
- 124200000
- Drug Name
- MDX2301, MDX2003, MDX2004
- Guidance
- FY26 total revenue $530M-$560M
- Revenue Yoy
- -17.1%
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.